Log in
Herbal antidepressant

Hypericum perforatum

Hypericum perforatum (St. John's Wort) is an over-the-counter herbal supplement used primarily for mild to moderate depression. Its active constituents hyperforin and hypericin are thought to inhibit reuptake of serotonin, norepinephrine, and dopamine. The most clinically important feature is its potent induction of cytochrome P450 enzymes and P-glycoprotein, leading to numerous significant drug interactions.

Practice questionsHigh-yield facts
Drug classHerbal antidepressant supplement
MechanismMonoamine reuptake inhibition; CYP450 and P-glycoprotein inducer
Main usesMild to moderate depression
Key adverse effectDrug interactions via enzyme induction
7 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

St. John's Wort contains multiple bioactive compounds, with hyperforin and hypericin considered the primary constituents responsible for antidepressant effects.

Antidepressant mechanism

  • Monoamine reuptake inhibition: Hyperforin inhibits reuptake of serotonin, norepinephrine, and dopamine by interfering with the reuptake transporters, similar to synthetic antidepressants but through a distinct mechanism
  • Monoamine oxidase inhibition: Weak inhibition of MAO-A and MAO-B has been demonstrated
  • GABA and glutamate effects: Modulation of GABA and glutamate receptor activity may contribute to anxiolytic effects
  • Sigma receptor binding: Interaction with sigma receptors may play a role in antidepressant activity

Enzyme induction

The most clinically significant pharmacological effect is potent induction of hepatic and intestinal enzymes:

  • CYP3A4 induction: The primary mechanism of drug interactions
  • CYP2C9, CYP1A2, and CYP2C19 induction: Additional cytochrome P450 pathways affected
  • P-glycoprotein induction: Increases efflux of substrate drugs from enterocytes and across blood-brain barrier
  • Pregnane X receptor (PXR) activation: The molecular mechanism underlying enzyme induction

Enzyme induction occurs within 1-2 weeks of starting therapy and reverses within 1-2 weeks after discontinuation.

High-yield for exams
  • St. John's Wort is a potent inducer of CYP3A4 and P-glycoprotein, causing numerous clinically significant drug interactions
  • Classic exam scenario: causes oral contraceptive failure and unintended pregnancy via enzyme induction
  • Contraindicated in organ transplant recipients — reduces cyclosporine/tacrolimus levels causing rejection risk
  • Causes photosensitivity due to hypericin; patients develop severe sunburn with minimal UV exposure
  • Serotonin syndrome risk when combined with SSRIs, SNRIs, triptans, or tramadol
  • Enzyme induction persists 1-2 weeks after discontinuation; drug interactions continue during washout
  • Mechanism: inhibits reuptake of serotonin, norepinephrine, and dopamine via hyperforin
  • Not appropriate for major depressive disorder; evidence supports use only in mild to moderate depression

Indications

St. John's Wort is used as an over-the-counter herbal remedy, primarily for:

Psychiatric conditions

  • Mild to moderate depression: The most common and best-studied indication; meta-analyses suggest efficacy comparable to conventional antidepressants for mild to moderate depression, though data quality varies
  • Seasonal affective disorder: Some evidence for effectiveness in mild winter depression
  • Anxiety disorders: Used traditionally, though evidence is limited

Other uses

  • Premenstrual syndrome: Limited evidence
  • Menopausal symptoms: Some traditional use for mood symptoms
  • Topical wound healing: Historical use for skin inflammation and minor wounds (hypericin has antimicrobial properties)

St. John's Wort is not recommended for major depressive disorder due to insufficient evidence and risk of undertreating serious depression. It is not approved by regulatory agencies as a pharmaceutical antidepressant in most countries but is available as a dietary supplement.

Pharmacokinetics

Absorption and distribution

  • Oral bioavailability: Variable depending on preparation and formulation; standardized extracts typically contain 0.3% hypericin
  • Peak plasma levels: Hypericin reaches peak concentrations 4-6 hours after oral administration
  • Food effects: Absorption may be enhanced with food
  • Tissue distribution: Hypericin distributes to tissues and crosses the blood-brain barrier

Metabolism and elimination

  • Hepatic metabolism: Hyperforin and hypericin undergo extensive hepatic metabolism
  • Half-life: Hypericin elimination half-life approximately 24-48 hours; hyperforin has a shorter half-life of 6-9 hours
  • Steady state: Achieved after approximately 4-7 days of regular dosing
  • Excretion: Primarily urinary and fecal excretion of metabolites

Special populations

  • Renal impairment: No specific dosage adjustments established
  • Hepatic impairment: Use with caution; may affect metabolism
  • Elderly: No specific pharmacokinetic data; start with lower doses
  • Pregnancy and lactation: Hyperforin and hypericin cross the placenta and are excreted in breast milk

Adverse effects

St. John's Wort is generally well-tolerated, but several adverse effects and safety concerns exist.

Common adverse effects

  • Gastrointestinal: Nausea, abdominal discomfort, diarrhea (most common)
  • Central nervous system: Dizziness, headache, restlessness, fatigue
  • Psychiatric: Anxiety, hypomania (rare but reported, particularly in patients with bipolar disorder)
  • Dermatologic: Dry mouth, skin reactions

Serious adverse effects

  • Photosensitivity: Hypericin causes phototoxic reactions with exposure to sunlight or UV light; patients should avoid excessive sun exposure and use sun protection
  • Serotonin syndrome: Risk when combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, tramadol)
  • Mania/hypomania: Can precipitate manic episodes in patients with undiagnosed bipolar disorder
  • Drug interaction-related adverse events: Loss of therapeutic efficacy of interacting medications is the most clinically significant safety concern

Withdrawal

  • Abrupt discontinuation may cause mild withdrawal symptoms similar to SSRI discontinuation syndrome (dizziness, nausea, anxiety)
  • Gradual tapering over 1-2 weeks is recommended

Contraindications and warnings

Absolute contraindications

  • Concomitant use with critical medications where enzyme induction could lead to treatment failure:
  • Immunosuppressants (cyclosporine, tacrolimus)
  • Antiretroviral drugs (protease inhibitors, NNRTIs)
  • Oral contraceptives
  • Warfarin
  • Digoxin
  • Chemotherapy agents (irinotecan, imatinib)
  • Severe depression or suicidal ideation: Not appropriate for major depressive disorder

Relative contraindications and warnings

  • Bipolar disorder: Risk of precipitating manic or hypomanic episodes
  • Schizophrenia or psychotic disorders: May worsen psychotic symptoms
  • Pregnancy: Insufficient safety data; potential for uterotonic effects and fetal hypericin exposure
  • Breastfeeding: Excreted in breast milk; colic and drowsiness reported in infants
  • Surgery: Discontinue at least 5 days before elective surgery due to potential interactions with anesthetics and risk of serotonin syndrome
  • Photosensitivity history: Use with extreme caution in fair-skinned individuals

Special populations

  • Children and adolescents: Safety and efficacy not established
  • Elderly: Increased sensitivity to CNS effects; higher risk of drug interactions due to polypharmacy
  • Organ transplant recipients: Absolute contraindication due to risk of transplant rejection from reduced immunosuppressant levels

Drug interactions

St. John's Wort has extensive and clinically significant drug interactions, primarily through CYP450 and P-glycoprotein induction. These interactions can reduce plasma concentrations of substrate drugs by 20-80%, leading to therapeutic failure.

Critical interactions (contraindicated)

  • Immunosuppressants: Cyclosporine, tacrolimus, sirolimus — risk of organ transplant rejection due to subtherapeutic levels
  • Antiretroviral therapy: Protease inhibitors (indinavir, ritonavir), NNRTIs (efavirenz, nevirapine) — risk of virologic failure and resistance
  • Oral contraceptives: Reduced efficacy leading to breakthrough bleeding and unintended pregnancy
  • Warfarin: Reduced INR and increased risk of thrombosis

Major interactions (avoid combination)

  • Other antidepressants: SSRIs, SNRIs, MAOIs, tricyclics — risk of serotonin syndrome when combined; reduced efficacy of synthetic antidepressants due to enzyme induction
  • Triptans: Sumatriptan, rizatriptan — increased risk of serotonin syndrome
  • Digoxin: Reduced digoxin levels and loss of therapeutic effect
  • Chemotherapy: Irinotecan, imatinib, vincristine — reduced efficacy
  • Anticonvulsants: May reduce levels of carbamazepine, phenytoin, valproate
  • Statins: Reduced simvastatin and atorvastatin levels
  • Benzodiazepines: Reduced alprazolam and midazolam levels
  • Calcium channel blockers: Reduced verapamil and nifedipine levels

Pharmacodynamic interactions

  • Photosensitizing drugs: Tetracyclines, thiazides, sulfonamides — additive photosensitivity risk
  • Serotonergic agents: Tramadol, dextromethorphan, linezolid — serotonin syndrome risk

Time course

Enzyme induction develops over 1-2 weeks and persists for 1-2 weeks after discontinuation. Patients should be monitored for loss of efficacy of interacting drugs during this period.

Clinical pearls

Exam-focused points

  • Classic USMLE scenario: Patient on oral contraceptives starts St. John's Wort for mild depression, then presents with unintended pregnancy — mechanism is CYP3A4 induction reducing contraceptive efficacy
  • Transplant rejection vignette: Organ transplant recipient with stable immunosuppressant levels starts St. John's Wort and develops acute rejection due to subtherapeutic cyclosporine or tacrolimus levels
  • Photosensitivity clue: Patient taking "herbal supplement" develops severe sunburn after minimal sun exposure — think St. John's Wort and hypericin-induced phototoxicity

Practice considerations

  • Always ask about supplements: Many patients do not consider herbal products as "real medications" and fail to report them
  • Standardization issues: Over-the-counter preparations vary widely in hyperforin and hypericin content; clinical trial results may not apply to all products
  • Duration of effect: Enzyme induction effects persist for 1-2 weeks after stopping; drug interactions continue during this washout period
  • Alternative for mild depression: If St. John's Wort is contraindicated due to drug interactions, consider conventional SSRIs with fewer interaction risks (escitalopram, sertraline)

Comparison with conventional antidepressants

  • Efficacy: Meta-analyses suggest comparable efficacy to SSRIs for mild to moderate depression, but study quality is heterogeneous
  • Side effect profile: Generally better tolerated than tricyclic antidepressants; comparable to SSRIs for common side effects
  • Drug interactions: Far more extensive and clinically significant than SSRIs
  • Regulatory status: Not FDA-approved as a drug; sold as dietary supplement with less stringent quality control

Patient counseling

  • Advise patients to inform all healthcare providers about St. John's Wort use
  • Emphasize sun protection and avoidance of tanning beds
  • Warn about reduced contraceptive efficacy; recommend barrier methods
  • Not appropriate for severe depression or as monotherapy for major depressive disorder
  • Discontinue at least 5 days before elective surgery
Mnemonic

"SAINT JOHN" for St. John's Wort interactions: Surgery (discontinue before), Antiretrovirals (contraindicated), Immunosuppressants (rejection risk), Not with SSRIs (serotonin syndrome), Transplants (avoid),ジョン (contraceptives fail), OCP failure, Hypericin (photosensitivity), Needs sun protection

Practice questions

1. A 28-year-old woman with a kidney transplant 2 years ago presents with fatigue and decreased urine output. She has been stable on cyclosporine therapy. Two weeks ago, she started taking an herbal supplement for mild depressive symptoms. Laboratory studies show an elevated serum creatinine and low cyclosporine trough level. Kidney biopsy shows tubulitis and mononuclear cell infiltration. Which of the following best explains her presentation?

Answer: B. This patient is experiencing acute transplant rejection due to St. John's Wort-induced CYP3A4 enzyme induction, which decreases cyclosporine blood levels to subtherapeutic range. St. John's Wort is contraindicated in transplant recipients for this reason. The biopsy findings of tubulitis and mononuclear infiltration are consistent with acute cellular rejection, not direct drug toxicity or autoimmune reaction. Option A is incorrect because P-glycoprotein induction would decrease, not increase, absorption.

2. A 32-year-old woman taking oral contraceptives and St. John's Wort for 3 weeks presents for emergency contraception after unprotected intercourse. She reports irregular spotting for the past week. Which of the following mechanisms best explains her increased pregnancy risk?

Answer: C. St. John's Wort induces CYP3A4, which metabolizes both estrogen and progestin components of oral contraceptives, reducing their blood levels by 15-50% and causing contraceptive failure. The breakthrough bleeding is a clinical sign of reduced hormone levels. This is one of the most high-yield drug interactions with St. John's Wort. The mechanism is enzyme induction, not altered absorption, renal elimination, receptor competition, or protein binding.

3. A 45-year-old man taking sertraline daily for depression decides to add St. John's Wort after reading about natural remedies online. Three days later, he presents to the emergency department with agitation, diaphoresis, tremor, hyperreflexia, and a temperature of 38.9°C (102°F). Which of the following is the most likely diagnosis?

Answer: C. This patient has serotonin syndrome from the combination of sertraline (an SSRI) and St. John's Wort (which also inhibits serotonin reuptake). The clinical triad of autonomic instability, neuromuscular abnormalities (hyperreflexia, tremor), and altered mental status is classic for serotonin syndrome. St. John's Wort should never be combined with other serotonergic agents. Neuroleptic malignant syndrome typically involves antipsychotics and presents with rigidity rather than hyperreflexia. The other options do not fit the clinical presentation or drug exposure.

Frequently asked questions

How does St. John's Wort work for depression?

St. John's Wort works by inhibiting the reuptake of serotonin, norepinephrine, and dopamine through its active constituent hyperforin, similar to conventional antidepressants but via a distinct mechanism. It also has weak monoamine oxidase inhibitory activity and affects GABA and glutamate neurotransmission. The antidepressant effects are thought to result from increased synaptic availability of these monoamine neurotransmitters, improving mood in patients with mild to moderate depression.

What are the side effects of St. John's Wort?

The most common side effects are gastrointestinal symptoms including nausea, abdominal discomfort, and diarrhea. Other frequent effects include dizziness, headache, fatigue, and restlessness. The most clinically significant adverse effect is photosensitivity — hypericin causes severe sunburn with minimal UV exposure. Serious risks include serotonin syndrome when combined with other antidepressants, potential for precipitating mania in bipolar disorder, and extensive drug interactions due to enzyme induction that can cause therapeutic failure of critical medications.

Can St. John's Wort interfere with birth control pills?

Yes, St. John's Wort significantly reduces the effectiveness of oral contraceptives by inducing CYP3A4, the enzyme that metabolizes estrogen and progestin. This enzyme induction decreases blood levels of contraceptive hormones by 15-50%, leading to breakthrough bleeding and increased risk of unintended pregnancy. Women taking hormonal contraceptives should avoid St. John's Wort or use additional barrier contraception. This is a classic exam scenario and one of the most clinically important interactions with this herbal supplement.

What is the difference between St. John's Wort and prescription antidepressants?

St. John's Wort is an over-the-counter herbal supplement with monoamine reuptake inhibition, while prescription antidepressants like SSRIs are FDA-approved drugs with standardized doses and proven efficacy. Both work for mild to moderate depression, but St. John's Wort has far more drug interactions due to CYP450 enzyme induction, affecting immunosuppressants, antiretrovirals, oral contraceptives, and warfarin. Prescription antidepressants have more consistent quality control and dosing. St. John's Wort is not appropriate for major depression or severe psychiatric illness.

Is St. John's Wort safe during pregnancy?

St. John's Wort safety in pregnancy is not well established and it is generally not recommended. The active compounds hyperforin and hypericin cross the placenta and expose the fetus. There is insufficient human data on teratogenicity, though animal studies suggest potential risks. Additionally, St. John's Wort may have uterotonic effects. Given the availability of better-studied prescription antidepressants with established pregnancy safety profiles, St. John's Wort should be avoided during pregnancy unless specifically recommended by a healthcare provider after risk-benefit assessment.

Conditions it is used for

Mild depressionModerate depressionSeasonal affective disorderAnxietyPremenstrual syndrome
FluoxetineSertralineEscitalopramCitalopramBupropionVenlafaxineMirtazapineAmitriptyline

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AX25

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.